Bristol-Myers’s Once-Daily Hepatitis C Drug Works in Study

Bristol-Myers Squibb Co.’s experimental hepatitis C drug worked in combination with two established medicines to cure as many as 83 percent of patients, a study found.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.